IMCR - CIK 0001671927
The table below shows Immunocore Holdings plc's cash flow statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.71M | $26.06M | $2.94M | -$49.21M | -$143.11M |
| Capital expenditure | $4.34M | $5.17M | $5.42M | $2.20M | $1.39M |
| Investing cash flow | -$16.34M | -$355.13M | -$5.42M | -$2.20M | -$1.28M |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - | - |
Immunocore Holdings plc reported operating cash flow of -$10.71M for fiscal year 2025. That is down 141.1% from $26.06M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow grew from -$143.11M (FY 2021) to -$10.71M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Financing cash flow | $12.37M | $343.88M | $34.35M | $145.44M | $288.19M |